Sumitomo Assumes Marketing of Tagamet Anti-Ulcer Medication
SmithKline Beecham Seiyaku K.K. (Head Office: Tokyo, President: Isao Muramatsu) and Sumitomo Pharmaceuticals Co., Ltd. (Head Office: Osaka, President: Masaaki Yokotsuka) reached an agreement on December 28, 2000, to transfer business in the ethical drug Tagamet from SmithKline Beecham to Sumitomo. Under the terms of the agreement, Sumitomo Pharmaceuticals will begin marketing the drug in mid-February 2001.
Originally developed by Smith, Kline & French Laboratories plc (now SmithKline Beecham plc), Tagamet is one of the world's most popular anti-ulcer medications. SmithKline Beecham Seiyaku has been manufacturing and marketing the drug in Japan under license from SmithKline Beecham plc.
SmithKline Beecham Seiyaku has concluded that it would be mutually beneficial to transfer the business of Tagamet to Sumitomo in the context of future business opportunities in Japan for the SmithKline Beecham Group.
Sumitomo Pharmaceuticals has enjoyed close cooperation with the Group, as it is entrusted with the manufacture of the general cold remedy Contac, an OTC drug marketed in Japan by SmithKline Beecham Seiyaku. Sumitomo believes that Tagamet will make an ideal addition to its product lineup.
After the onset of the marketing of the anti-ulcer remedy, Sumitomo Pharmaceuticals will disseminate information on the drug, as well as promote sales.
Tagamet tablets (200 mg, 400 mg), injection (200 mg), fine granule preparations (20%)